Roche Diagnostics Growth Flattens As China Reforms Bite; Bets On US Manufacturing, CGM For Growth

Diagnostics Strategy Pivots To US Tech Transfer And Product Mix Evolution Post-China Disruption

 
• By Shubham Singh
  
Matthew Sause, CEO of Roche Diagnostics, said that while China remains a key market for Roche, the pricing reforms had a heavy impact, and their effect will continue throughout 2025. Picture Courtesy: Shutterstock

More from Strategy

More from Business